SESSION PROGRAM

Tuesday
20 February 2018

08:00  REGISTRATION OPENS
Coffee/tea available from 9:00 - 10:30

10:30 – 12:15  OPENING SESSION

Shahjehan Co-Chairs: Danilo Casimiro, former Chief Scientific Officer, Aeras (USA) | Soumya Swaminathan, former Director-General, Indian Council of Medical Research (India) | David Lewinsohn, Chair, Stop TB Partnership Working Group on New Vaccines (USA) | Nick Drager, Executive Director, Tuberculosis Vaccine Initiative (Netherlands)

Overview of the TB epidemic globally and in India
Soumya Swaminathan, Deputy Director General of Programmes, World Health Organization (Switzerland)

Civil society perspective on the need for new TB vaccines
Blessina Kumar, Global Coalition of TB Activists (India)

Access and affordability for new TB vaccines
Hendrik Bekedam, World Health Organization Representative to India, WHO Country Office (India)

The potential public health impact of new TB vaccines
Richard White, Professor, London School of Hygiene and Tropical Medicine and Director, TB Modelling and Analysis Consortium (UK)

Partnerships and collaboration in TB vaccine R&D
Renu Swarup, Senior Advisor, Department of Biotechnology, Ministry of Science & Technology (India)

India’s commitment to end TB
Manoj Jhalani, Additional Secretary and Mission Director, National Health Mission, Ministry of Health & Family Welfare, Government of India

12:15 – 13:00  KEYNOTE ADDRESS
Shahjehan Why we need a vaccine to control TB and what we need to learn to develop an effective vaccine
Barry R. Bloom, Joan L. and Julius H. Jacobson Research Professor of Public Health, Harvard University (USA)

13:00 – 14:00  LUNCH, RANI BAGH LAWN

14:00 – 16:00  PLENARY SESSION 1: INCREASING PROBABILITY OF SUCCESS AND MAXIMIZING IMPACT

Shahjehan Co-Chairs: Willem Hanekom, Bill & Melinda Gates Foundation (USA) | Gagandeep Kang, Translational Health Science and Technology Institute (India)

Vaccine strategies to address drug-resistant tuberculosis
Gavin Churchyard, The Aurum Institute (South Africa)

Decision-making in TB vaccine development: the stage-gate process
Georges Thiry, Aeras/Tuberculosis Vaccine Initiative Joint Working Group on Stage-Gates (France)

Can biomarkers advance the development of new TB vaccines?
Hazel M. Dockrell, London School of Hygiene and Tropical Medicine (UK)

Human TB Challenge – you can do that?
Eric J. Rubin, Harvard T.H. Chan School of Public Health (USA)

Enriching cohorts for smaller, quicker, more efficient TB vaccine studies
Dereck Tait, Aeras (South Africa)

16:15 – 17:45  POSTER DISCUSSION/PRESENTATION SESSIONS

Roshanara Poster Discussion 1: Basic Vaccine Concepts and Correlates of Protective Immunity
Sheesh Mahal Poster Discussion 2: Diagnostics and Epidemiology
Mumtaz Mahal Poster Viewing: Novel Vaccine Concepts; Chemistry, Manufacturing and Controls

See Poster Program for additional details
Coffee/tea to be served by the session room
17:45 – 18:30  NETWORKING AND REFRESHMENTS, RANI BAGH LAWN
18:30 – 20:00  INAUGURAL CEREMONY

Shahjehan  Co-Chairs: Nick Drager, Executive Director, TuBerculosis Vaccine Initiative (Netherlands) | Lucica Ditl, Executive Director, Stop TB Partnership (Switzerland)

Prevention is better than cure: A survivor story
Mona Balani, Touched by TB (India)

Regional efforts to bending the curve
Poonam Khetrapal Singh, WHO Regional Director for South-East Asia (India)

Translating rhetoric into action: Transforming the global TB response
Soumya Swaminathan, Deputy Director General of Programmes, World Health Organization (Switzerland)

India’s mission to strengthen vaccine research
Anupriya Patel, Honourable Minister of State, Ministry of Health & Family Welfare, (India)

Research, innovation and partnerships as the pathway to success
Harsh Vardhan, Honourable Union Minister, Ministry of Science & Technology and Earth Sciences, Ministry of Environment, Forest & Climate Change (India)

20:00 – 21:30  FORUM DINNER, RANI BAGH LAWN

Wednesday
21 February 2018

09:00 – 11:00  PLENARY SESSION 2: CLINICAL DEVELOPMENT OF NEW TB VACCINES

Shahjehan  Co-Chairs: Souleymane Mboup, Institut de Recherche en Santé, de Surveillance Epidemiologique et de Formations (Senegal) | Sanjay Mehendale, Indian Council of Medical Research (India)

PS-06  A critical juncture in tuberculosis vaccine clinical development: overview of progress
Ann M. Ginsberg, Aeras (USA)

PS-07  Community engagement and Good Participatory Practice guidelines for TB vaccine research and development
Moses Zimba, Centre for Infectious Disease Research in Zambia (Zambia)

PS-08  Evaluating potential of vaccine(s) in preventing disease in healthy household contacts of TB patients
Kavita Singh, Multi Vaccines Development Program (India)

PS-09  A new TB vaccine on the horizon
Umesh Shaligram, Serum Institute of India Ltd Pvt (India)

PS-10  Prevention of infection with Mycobacterium tuberculosis by H4:IC31 vaccination or BCG revaccination in healthy adolescents: results of a randomized controlled trial
Mark Hatherill, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa)

11:00 – 11:30  COFFEE/TEA BREAK

11:30 – 13:00  BREAKOUT SESSION 1: BASIC SCIENCE RESEARCH

Shahjehan  Co-Chairs: Katrin Eichelberg, National Institute for Allergy and Infectious Diseases, National Institutes of Health (USA) | Rajesh Gokhale, National Institute of Immunology (India)

OA-01  How EsxH controls host cellular responses to Mycobacterium tuberculosis?
Ekansh Mittal, Washington University School of Medicine (USA)

OA-02  Elevated cyclic AMP inhibits Mycobacterium tuberculosis-stimulated T cell IFN-γ secretion through type I protein kinase A
Buka Samten, University of Texas Health Science Center at Tyler (USA)

OA-03  A TOLLIP deficiency allele, rs5743854, is associated with decreased IncRNA TOLLIP-AS1 expression, BCG-specific T-cell memory phenotypes, and increased TB susceptibility
Javeed Ali Shah, University of Washington (USA)

OA-04  Pulmonary mucosal BCG vaccination shows protection of infection in a novel repeated ultra-low dose challenge model in rhesus macaques
Frank A.W. Verreck, Biomedical Primate Research Centre (Netherlands)
Memory, activation and functional profiles of Mycobacterium tuberculosis-specific CD4 T cells in recent QFT converters
Cheleka Anne-Marie Mpande, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa)

Protein kinase G confers survival advantage to Mycobacterium tuberculosis during latency like conditions
Mehak Zahoor Khan, National Institute of Immunology (India)

**BREAKOUT SESSION 2: CLINICAL RESEARCH**

**Jehangir** Co-Chairs: Sanjay Gurunathan, Sanofi Pasteur (USA) | Randeep Guleria, All India Institute of Medical Sciences (India)

**OA-07** DAR-901: an inactivated whole cell NTM booster vaccine
C. Fordham von Reyn, Geisel School of Medicine at Dartmouth (USA)

**OA-08** A randomized, double-blind, dose-escalation clinical trial of MTBVAC compared to BCG Vaccine SSI, in newborns living in a tuberculosis endemic region
Michele Tameris, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa)

**OA-09** Clinical development of ID93+GLA-SE as a prophylactic or therapeutic vaccine for tuberculosis
Tracey Ann Day, Infectious Disease Research Institute (USA)

**OA-10** Use of oral inactivated Mycobacterium marinum as a prophylactic vaccine for tuberculosis
Pere Joan Cardona, Institut Germans Trias i Pujol (Spain)

**OA-11** Phase III, placebo-controlled, 2:1 randomized, double-blinded trial of tableted immunotherapeutic TB vaccine (V7) containing 10 microgram of heat-killed M. vaccae
Aldar S. Bourinbair, Immunitor LLC (Mongolia)

**OA-12** Randomized open phase 1 trial of TB/FLU-01L vaccine administrated intranasally or sublingually for immunotherapy of pulmonary tuberculosis
Marina Stukova, Research Institute of Influenza (Russia)

---

13:00 – 14:00 LUNCH – RANI BAGH LAWN

14:00 – 16:00 PLENARY SESSION 3: NOVEL APPROACHES TO TB VACCINE RESEARCH & DEVELOPMENT

**Shahjehan** Co-Chairs: JoAnne Flynn, University of Pittsburgh (USA) | Anil Tyagi, Guru Gobind Singh Indraprastha University (India)

**PS-11** The route of BCG vaccination determines immunity and protection against Mycobacterium tuberculosis infection in non-human primates
Robert Seder, National Institute of Allergy and Infectious Diseases, National Institutes of Health (USA)

**PS-12** Vaccination following mycobacterial exposure
Thomas J. Scriba, South African Tuberculosis Vaccine Initiative (SATVI), University of Cape Town (South Africa)

**PS-13** Cytomegalovirus (CMV)-based TB vaccines
Aurelio Bonavia, Vir Biotechnology (USA)

**PS-14** Nucleic acid vaccines for tuberculosis
Jeffrey B. Ulmer, GSK Vaccines (USA)

**PS-15** Protective potential of Mycobacterium indicus pranii (MIP) and the underlying mechanisms in animal models of tuberculosis
Sangeeta Bhaskar, National Institute of Immunology (India)

16:00 – 16:30 COFFEE/TEA BREAK

16:30 – 18:00 POSTER DISCUSSION SESSIONS

**Roshanara** Poster Discussion 3: Preclinical Research

**Sheesh Mahal** Poster Discussion 4: Clinical Research and Community Engagement

**Mumtaz Mahal** Poster Viewing: Basic Science Research, Biomarkers and Correlates, Epidemiology

See Poster Program for additional details

18:00 – 20:00 NETWORKING RECEPTION AND POSTER VIEWING

Cultural performance followed by networking and poster viewing
Posters on display in Mumtaz Mahal, Sheesh Mahal, and Roshanara
Food and drink stations will be located in Shahjehan and Roshanara
### Thursday
22 February 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:15 – 08:45</td>
<td>SATELLITE SESSION: PANEL DISCUSSION AND AUDIENCE Q&amp;A ON THE H4:IC31®/BCG REVACCINATION POI TRIAL RESULTS</td>
</tr>
<tr>
<td>Jehangir</td>
<td>Organized by Sanofi Pasteur and Aeras</td>
</tr>
<tr>
<td></td>
<td>Speakers/content to be announced</td>
</tr>
<tr>
<td></td>
<td>Coffee/tea and light snacks provided</td>
</tr>
<tr>
<td>09:00 – 11:00</td>
<td>PLENARY SESSION 4: THE CUTTING EDGE: TRANSLATING SCIENTIFIC ADVANCES INTO NEW TB VACCINES</td>
</tr>
<tr>
<td>Shahjehan</td>
<td>Co-Chairs: Peter Andersen, Statens Serum Institute (Denmark)</td>
</tr>
<tr>
<td>PS-16</td>
<td><strong>Predictive biosignatures to improve tuberculosis vaccine development</strong></td>
</tr>
<tr>
<td></td>
<td>Stefan H.E. Kaufmann, Max Planck Institute for Infection Biology (Germany)</td>
</tr>
<tr>
<td>PS-17</td>
<td><strong>Harnessing the power of innate immunity in vaccines against TB</strong></td>
</tr>
<tr>
<td></td>
<td>Maziar Divangahi, McGill University (Canada)</td>
</tr>
<tr>
<td>PS-18</td>
<td><strong>Donor unrestricted T-cells (DURTS)</strong></td>
</tr>
<tr>
<td></td>
<td>David Lewinsohn, Oregon Health &amp; Science University (USA)</td>
</tr>
<tr>
<td>PS-19</td>
<td><strong>Tissue-resident memory T-cells in infection and inflammation</strong></td>
</tr>
<tr>
<td></td>
<td>Chang Oik Park, Yonsei University College of Medicine (South Korea)</td>
</tr>
<tr>
<td>PS-20</td>
<td><strong>Targeting checkpoint inhibitor-PD-1 for enhancing efficacy of therapeutic vaccines in tuberculosis</strong></td>
</tr>
<tr>
<td></td>
<td>Dipendra K. Mitra, All India Institute of Medical Sciences (India)</td>
</tr>
<tr>
<td>11:00 – 11:30</td>
<td>COFFEE/TEA BREAK</td>
</tr>
<tr>
<td>11:30 – 13:00</td>
<td>BREAKOUT SESSION 3: NOVEL VACCINE CONCEPTS AND PRECLINICAL RESEARCH</td>
</tr>
<tr>
<td>Shahjehan</td>
<td>Co-Chairs: Luciana Leite, Instituto Butantan (Brazil)</td>
</tr>
<tr>
<td>OA-13</td>
<td><strong>Stress-response deficient attenuated Mycobacterium tuberculosis as next-gen TB vaccines</strong></td>
</tr>
<tr>
<td></td>
<td>Deepak Kaushal, Tulane National Primate Research Center (USA)</td>
</tr>
<tr>
<td>OA-14</td>
<td><strong>Mechanisms of attenuation and protection of MTBVAC, a live attenuated tuberculosis vaccine moving to efficacy clinical trials</strong></td>
</tr>
<tr>
<td></td>
<td>Carlos Martin, University of Zaragoza (Spain)</td>
</tr>
<tr>
<td>OA-15</td>
<td><strong>Increased efficacy of chemotherapy against Mycobacterium tuberculosis by additive immunotherapy using a multistage MVA vaccine</strong></td>
</tr>
<tr>
<td></td>
<td>Stéphane Leung-Theung-Long, Transgene (France)</td>
</tr>
<tr>
<td>OA-16</td>
<td><strong>Immunogenicity and efficacy evaluation of multiple ChAd3-5Ag ± MVA-5Ag prime-boost vaccine regimens in rhesus macaques</strong></td>
</tr>
<tr>
<td></td>
<td>Agnes Laurence Chenine, Aeras (USA)</td>
</tr>
<tr>
<td>OA-17</td>
<td><strong>Recombinant BCG expressing ESX-1 of Mycobacterium marinum combines low virulence with cytosolic immune signaling and improved tuberculosis protection</strong></td>
</tr>
<tr>
<td></td>
<td>Matthias I. Gröschel, Institute Pasteur, Paris (France); University Medical Center Groningen (Netherlands)</td>
</tr>
<tr>
<td>OA-18</td>
<td><strong>Novel mucosal TB vaccine candidates generated by EMI-TB consortium</strong></td>
</tr>
<tr>
<td></td>
<td>Rajko Reljic, St. George's Medical School, University of London (UK)</td>
</tr>
<tr>
<td>Jehangir</td>
<td>BREAKOUT SESSION 4: BIOMARKERS, CORRELATES AND EPIDEMIOLOGY</td>
</tr>
<tr>
<td>OA-19</td>
<td><strong>NK cells and memory-like NK cells as immunological markers of protection against latent TB conversion in household contacts of TB patients</strong></td>
</tr>
<tr>
<td></td>
<td>Kamakshi Prudhula Devalraju, Bhagwan Mahavir Medical Research Centre (India)</td>
</tr>
<tr>
<td>OA-20</td>
<td><strong>Gene expression profiles of pediatric tuberculosis patients and exposed controls from India</strong></td>
</tr>
<tr>
<td></td>
<td>Jeffrey A Tornheim, Johns Hopkins University School of Medicine (USA)</td>
</tr>
<tr>
<td>OA-21</td>
<td><strong>Evaluating immune correlates of risk of Mycobacteria tuberculosis infection in humans</strong></td>
</tr>
<tr>
<td></td>
<td>Iman Satti, University of Oxford (UK)</td>
</tr>
<tr>
<td>OA-22</td>
<td><strong>Maximising impact of the TB vaccine pipeline – mathematical modelling to inform target product profiles</strong></td>
</tr>
<tr>
<td></td>
<td>Rebecca Claire Harris, London School of Hygiene and Tropical Medicine (UK)</td>
</tr>
</tbody>
</table>
Incidence of tuberculosis disease among household contacts of adult pulmonary tuberculosis patients in India – a multi-centric cohort study
Sriram Selvaraju, National Institute for Research in Tuberculosis (India)

High risk for tuberculosis infections among medical and nursing trainees in India
Aarti Avinash Kinikar, Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospital (India)

13:00 – 14:00 LUNCH - RANI BAGH LAWN
14:00 – 16:30 PLENARY SESSION 5: PARTNERING FOR PROGRESS AND INNOVATION

Shahjehan
Co-Chairs/Facilitators: Ole Olesen, European & Developing Countries Clinical Trials Partnership (Netherlands) | Renu Swarup, Biotechnology Industry Research Assistance Council (India); Department of Biotechnology (India)

Roundtable discussion featuring:
- Fareed Abdullah, South African Medical Research Council (South Africa)
- Shelly Batra, Operation AHSA (India)
- Willem Hanekom, Bill & Melinda Gates Foundation (USA)
- Michel Kazatchkine, Global Health Centre, Graduate Institute for International and Development Studies (Switzerland)
- Rajiv I. Modi, Chairman of the Confederation of Indian Industry National Council on Pharmaceuticals (India) and Cadila Pharmaceuticals (India)
- Jacqueline Shea, Aeras (USA)

CLOSING SESSION
Co-Chairs: Danilo Casimiro, former Aeras (USA) | Sanjay Mehandele, Acting Director-General, Indian Council on Medical Research (India) | David Lewinsohn, Stop TB Partnership Working Group on New Vaccines (USA) | Nick Drager, TuBerculosis Vaccine Initiative (Netherlands)

Closing Address
Lucica Ditiu, Stop TB Partnership (Switzerland)

---

Friday 23 February 2018

SITE VISITS (Pre-registration Required)

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 – 11:30</td>
<td>International Centre for Genetic Engineering and Biotechnology</td>
</tr>
<tr>
<td>9:30 – 13:00</td>
<td>National Institute for Tuberculosis and Respiratory Diseases</td>
</tr>
<tr>
<td>8:30 – 12:30</td>
<td>Operation ASHA</td>
</tr>
<tr>
<td>8:30 – 14:00</td>
<td>Translational Health Science and Technology Institute</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>-----------</td>
<td>----------------------------------------------</td>
</tr>
<tr>
<td>16:15</td>
<td>POSTER DISCUSSION 1: BASIC VACCINE CONCEPTS AND CORRELATES OF PROTECTIVE IMMUNITY</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>17:45</td>
<td>POSTER DISCUSSION 2: DIAGNOSTICS AND EPIDEMIOLOGY</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| PD-28 | Optimization and interpretation of serial QuantiFERON testing to measure acquisition of M. tuberculosis infection  
Elisa Nemes, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa) |
| PD-29 | Updating the recommended age of BCG vaccination? Modelling the potential impact on global paediatric TB mortality  
Partho Roy, London School of Hygiene and Tropical Medicine (UK)  
*Presented by Rebecca Harris, London School of Hygiene and Tropical Medicine (UK)* |
| PD-30 | Do we have identified target groups and a population based strategy for vaccination against tuberculosis to cut down transmission?  
U.D. Gupta, National JALMA Institute for Leprosy and Other Mycobacterial Diseases (India) |
| PD-31 | TB Infection among household contacts: Preventive therapy for all?  
Chandra Kumar Dolla, Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospital (India) |
| PD-32 | Infection free “resistors” among household contacts of culture-confirmed adult pulmonary TB cases  
Vidya Mave, Byramjee Jeejeebhoy Government Medical College - Johns Hopkins University Clinical Research Site (India) |
| PD-33 | Incidence of Mycobacterium tuberculosis infection among household contacts of adult pulmonary tuberculosis cases in India  
Mandar Paradkar, Byramjee Jeejeebhoy Government Medical College Clinical Research Site (India) |

**Mumtaz Mahal**

**POSTER VIEWING: NOVEL VACCINE CONCEPTS; CHEMISTRY, MANUFACTURING AND CONTROLS**

| PA-01 | The impact of previous BCG vaccination in enhancing the effectiveness of tuberculosis drugs to control mycobacterial growth ex-vivo  
Satria Arief Prabowo, London School of Hygiene and Tropical Medicine (UK) |
| PA-02 | The role of DPP4 and antagonist CXCL10 in the pathogenesis of TB, an opportunity for vaccines and HDT?  
Morten Ruhwald, Statens Serum Institut (Denmark) |
| PA-03 | Mycobacterium tuberculosis H37Rv cell wall isolated poly L-glutamines as novel Th1-biased adjuvant  
Manish Gupta, Jawaharlal Nehru University (India) |
| PA-04 | De novo arginine biosynthesis pathway of Mycobacterium tuberculosis: A novel drug target and potential vaccine candidate  
Sangeeta Tiwari, Albert Einstein College of Medicine (USA) |
| PA-05 | Epitope-based vaccine design for Mycobacterium tuberculosis strains through pan-genomic reverse vaccinology  
Ravina Madhulitha Nalamolu, Sri Venkateswara Institute of Medical Sciences University (India) |
| PA-06 | Development of a recombinant BCG vaccine expressing a monomeric form of ESAT-6  
Makram Essafi, Institut Pasteur de Tunis (Tunisia) |
| PA-07 | Insights into mycobacterial membrane vesicles: a potential subunit vaccine candidate  
Praapti Jayaswal, Translational Health Science and Technology Institute (India) |
| PA-08 | Assessment of the protective effect, against tuberculosis, of a new vaccine composition  
Rania Bouzeyen, Institut Pasteur de Tunis (Tunisia) |
| PA-09 | Immunological activity of the fusion protein consisted of the major secretory protein of Mycobacterium tuberculosis  
Hyun Shik Bae, Chungnam National University (South Korea) |
| PA-10 | Synthetic polysaccharide conjugate vaccines expressing Mycobacterium tuberculosis antigens induce high-titer antibody responses in mice, guinea pigs, and rabbits  
Dominick Laddy, Aeras (USA) |
| PA-11 | Rv2882c-Rv20xxx, a novel immunostimulatory antigen of Mycobacterium tuberculosis, activates bone-marrow derived dendritic cell  
Ki-Won Shin, College of Medicine, Chungnam National University (South Korea) |
| PA-12 | Mycobacterium tuberculosis protein Rv2299c fused-ESAT-6 subunit vaccine confers improved protection against the hypervirulent strain HN878 in mice  
Seunga Choi, College of Medicine, Chungnam National University (South Korea) |
| PA-13 | Evaluation of attenuated strains as auxotrophic vaccines against Mycobacterium tuberculosis  
Tannu Priya Gosain, Translational Health Science and Technology Institute (India) |
**CHEMISTRY, MANUFACTURING AND CONTROLS**

PA-14  Miniaturized fluorescence adapter for fluorescence sputum smear microscopy using bright-field microscope  
Pooja Singh, IIT Delhi (India)

PA-15  Development of an innovative, rapid, affordable and automated system for selective enrichment, isolation and detection of MTB in sputum sample  
Saumya Singh, IIT Delhi (India)

PA-16  Comparison of pellicle and liquid grown BCG reference strains in standard BCG batch release assays and protection studies  
Megan Fitzpatrick, Aeras (USA)

---

**Wednesday, 21 February 2018**

<table>
<thead>
<tr>
<th>16:30 – 18:00</th>
<th>POSTER DISCUSSION 3: PRECLINICAL RESEARCH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roshanara</td>
<td>Facilitators: Danilo Casimiro, former Aeras (USA)</td>
</tr>
</tbody>
</table>
| PD-10         | Early and local immune mechanisms of TB disease progression and control upon ultra-low dose infection in rhesus versus cynomolgus macaques  
Karin Dijkstra, Biomedical Primate Research Centre (Netherlands)  
| PD-11         | Experimental evaluation of a novel microneedle device for BCG vaccination  
Jungho Kim, International Tuberculosis Research Center (South Korea)  
**Presented by Jake Whang, International Tuberculosis Research Center (South Korea)** |
| PD-12         | Role of BCG encapsulated alginate particles in activation of bone marrow derived dendritic cells for providing better immune response against TB  
Ashwani Kesarwani, National Institute of Immunology, Jamia Hamdard (India)  
| PD-13         | BioA mutant of Mycobacterium tuberculosis shows severe growth defect and imparts protection against tuberculosis in guinea pigs  
Ritika Kar Bahal, University of Delhi South Campus (India) |
| PD-14         | Animal dose response curve predicts lower optimal tuberculosis vaccine dose in humans: The use of vaccine Immunostimulation/Immunodynamic modelling methods to inform vaccine dose decision-making  
Sophie Rhodes, London School of Hygiene and Tropical Medicine (UK)  
**Presented by Richard White, London School of Hygiene and Tropical Medicine (UK)** |
| PD-15         | T cell immunity in the lung and protection following aerosol, intravenous, or intradermal administration of BCG in nonhuman primates  
Patricia Darrah, National Institute of Immunology and Infectious Diseases, National Institutes of Health (USA) |
| PD-16         | A recombinant BCG-LTAK63 strain induces increased innate and long-term immunity correlating with enhanced protection against tuberculosis  
Luciana Leite, Instituto Butantan (Brazil) |
| PD-17         | Recombinant BCG-LTAK63 strain induces lower immunopathological effects and superior protection against tuberculosis in BALB/c and C57BL/6 mice  
Carina Santos, Instituto Butantan (Brazil) |
| PD-18         | Intranasal vaccination with Mycobacterium indicus pranii leads to infiltration of protective memory T-cells in lung airway lumen  
Ananya Gupta, National Institute of Immunology (India) |
| PD-19         | Boosting with recombinant MVA expressing α-crystallin antigen of M. tuberculosis augments the protection imparted by BCG against tuberculosis in guinea pigs  
Prachi Nangpal, University of Delhi South Campus (India) |
| PD-20         | A single dose nanoparticulate vaccine approach against tuberculosis  
Manish Gupta, Jawaharlal Nehru University (India) |
| PD-21         | Passive vaccination with human IgA protects against MDR-TB infection in mice  
Andy Tran, St. George’s University of London (UK) |
### Sheesh Mahal

**Facilitators:** Souleymane Mboup, Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formations (Senegal) | Lorraine Misquith, Lawyers Collective; Global Coalition of TB Activists (India)

**PD-34** Immunogenicity of AERAS-404 or BCG revaccination in a prevention of established M. tuberculosis infection efficacy trial  
Virginie Rozot, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa)

**PD-35** Phase 1 clinical trial to evaluate the safety and immunogenicity of an adenovirus-based tuberculosis vaccine (Ad5Ag85A) administered by aerosol to healthy volunteers  
Fiona Mary Small, McMaster University (Canada)

**PD-36** Dose definition of the novel TB vaccine ID93 + GLA-SE for TB endemic countries  
Adam Penn-Nicholson, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa)

**PD-37** The Toll-like receptor 4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine  
Tracey Ann Day, Infectious Disease Research Institute (USA)

**PD-38** Safety and immunogenicity of H56:IC31 in HIV negative adults with and without latent tuberculosis (TB) infection  
Angelique Kani Kani Luabeya, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa)

**PD-39** Impact of implementing an effective community engagement strategy on retention rates in a Phase 2b TB disease prevention vaccine trial in South Africa, Zambia, and Kenya  
Anja van der Westhuizen, Aeras Africa (South Africa)

**PD-40** Building a portfolio of community engagement projects to enhance TB  
Michele Tameris, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa)

**PD-41** Drama as a community engagement tool to raise TB awareness  
Kelvin Vollenhoven, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa)

**PD-42** Leveraging libraries to raise awareness about TB on World TB Day  
Kelvin Vollenhoven, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa)

**PD-43** Using eCompliance for tracking patients and ensuring accuracy of data in vaccine trials  
Shelly Batra, Operation ASHA (India)

### Mumtaz Mahal

**POSTER VIEWING: BASIC SCIENCE RESEARCH, BIOMARKERS AND CORRELATES, EPIDEMIOLOGY**

**PA-17** Functional, antigen-specific stem cell-like memory (Tscm) CD4+ T cells are induced by human Mycobacterium tuberculosis infection  
Cheleka Anne-Marie Mpande, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa)

**PA-18** Activation of L-type voltage gated calcium channel in macrophages suppresses protective responses during Mycobacterium tuberculosis infection  
Deepika Sharma, University of Delhi (India)

**PA-19** Role of phosphorylation on secretion in Mycobacterium tuberculosis and its impact on its survival  
Basanti Malakar, National Institute of Immunology (India)

**PA-20** Challenges in detecting TB drug resistance in a field setting in Southwestern Uganda  
Patrick Orkiriza, Mbarara University of Science and Technology (Uganda)

**PA-21** Calcimycin induced autophagy decreases mycobacterial growth in THP-1 cells through P2RX7 dependent pathway mediated by intracellular calcium  
Shradha Mawatwal, National Institute of Technology, Rourkela (India)

**PA-22** Phenotypic adaptation to drug treatment in Mycobacterium tuberculosis is mediated by DNA gyrase  
Eira Choudhary, Translational Health and Science Technology Institute (India)

**PA-23** Assessment of anti-mycobacterial activity of some selected Congolese medicinal plants  
Gedeon Ngiala Bongo, University of Kinshasa (Democratic Republic of Congo)

**PA-24** Various aspects of GTPases towards its essentiality in survival and pathogenesis of Mycobacterium tuberculosis H37Rv  
Shivangi, CSIR-Institute of Genomics and Integrative Biology (India)
PA-25 Cytokines, matrix metalloproteinases, angiogenic factors and acute phase proteins as biomarkers in tuberculous lymphadenitis
Gokul Raj Kathamuthu, National Institute for Research in Tuberculosis (NIRT)-NIH-ICER (India)

PA-26 Urine IP-10 as a biomarker of therapeutic response in patients with active pulmonary tuberculosis
Hyejon Lee, Yonsei University College of Medicine (South Korea)
Presented by Bora Sim, Yonsei University College of Medicine (South Korea)

EPIDEMIOLOGY

PA-27 Sputum sample collection for diagnosis of pediatric pulmonary tuberculosis, does method and site of sample collection matter?
Willy Ssengooba, Makerere University (Uganda)

PA-28 Tuberculosis massive active case discovery in East Jakarta 2016-2017: the role of Ketuk Pintu Layani Dengan Hati (KPLDH) and Juru Pemantau Batuk (Jumantuk) cadre programs
Ngabila Salama, East Jakarta Health Office (Indonesia)

PA-29 Clinical profile of tuberculous meningitis in a tertiary care center in India
Anita Basavaraj, Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospital (India)